SOLVE FSHD Supports the FSHD Canada Foundation in Funding of US$1.2M in Multidisciplinary Biomarker Grants
The FSHD Canada Foundation acknowledges the generous support of SOLVE FSHD towards funding these grants.
- The FSHD Canada Foundation acknowledges the generous support of SOLVE FSHD towards funding these grants.
- These biomarker grant projects were prioritized by SOLVE FSHD based on their proposed potential to impact clinical trial outcomes and accelerate timelines for the development of FSHD therapeutics.
- The goal is to identify a biomarker that changes early and predicts disease progression, says Dr. Eva Chin, SOLVE FSHD Executive Director.
- SOLVE FSHD is funding innovative biotech and biopharma research and development activities that accelerate novel treatments of Facioscapulohumeral muscular dystrophy (FSHD) treatment.